Skip to main content
SpringerLink
Log in

Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Advances in immunosuppressive therapy allowed renal transplantation to become the treatment of choice for suitable candidates with (end stage renal disease) ESRD. The post-transplant therapeutic strategy is difficult due to narrow therapeutic indices for the currently used immunosuppressive drugs. Inter-individual differences in drug bioavailability are related to genetic and non genetic factors. The idea of targeted and personalized therapy is to achieve therapeutic success. The empirical dose has lost its value in the post-transplant therapy and an individualized dosage regimen must be established. Interindividual heterogeneity in expression of ABCB1 and CYP3A4 has been suspected to be one of the factors resulting in cyclosporine (CsA) pharmacokinetic variation. This study aimed to investigate the impact of inter-individual CYP3A4 rs4646437C>T and MDR1 G2677T/A polymorphisms on cyclosporine dose requirements among a sample of renal transplant Egyptian recipients. Fifty adult Egyptian patients on CsA were genotyped for CYP3A4 rs4646437C>T and MDR1 G2677T/A and correlated with CsA dose requirement and dose-adjusted CsA (C0) blood levels at 3, 6, and 9 months post transplantation. CYP3A4 rs4646437C>T influenced significantly cyclosporine kinetics, the T carriers requiring higher cyclosporine dose. Daily dose requirements were also significantly higher in T allele MDR1 2677G>T GG genotype as compared to GT/TT genotypes at 3, 6, and 9 months post transplantation. Genotyping of both CYP3A4 and MDR1 SNPs may be helpful in providing pre-transplant pharmacogenetic information to individualize CsA dosing. Heterozygous CT genotype is the most frequent CYP3A4 rs4646437C>T genotype in the studied group of Egyptian population (48 %) followed by CC genotype and TT genotype. Daily dose requirements were significantly higher in T allele MDR1 2677G>T GG genotype as compared to GT/TT genotypes at 3, 6, and 9 months post transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Singh R, Srivastava A, Kapoor R, K Sharma R, D Mittal R (2009) Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn Schmiedebergs Arch Pharmacol 380(2):169–177

    Article  CAS  PubMed  Google Scholar 

  2. Crettol S, Venetz JP, Fontana M, Aubert JD, Pascual M, Eap CB (2008) CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit 30(6):689–699

    Article  CAS  PubMed  Google Scholar 

  3. Yu SF, Wu LH, Zheng SS (2006) Genetic factors for individual administration of immunosuppressants in organ transplantation. Hepatobiliary Pancreat Dis Int 5(3):337–344

    CAS  PubMed  Google Scholar 

  4. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ (2003) Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13(2):89–95

    Article  CAS  PubMed  Google Scholar 

  5. Wang Y, Wang C, Li J, Wang X, Zhu G, Chen X et al (2009) Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Eur J Clin Pharmacol 65(3):239–247

    Article  CAS  PubMed  Google Scholar 

  6. Uesugi M, Masuda S, Katsura T, Oike F, Takada Y, Inui K (2006) Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 16(2):119–127

    Article  CAS  PubMed  Google Scholar 

  7. Salameh G, Al Hadidi K, El Khateeb M (2012) Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population. Environ Toxicol Pharmacol 34(1):23–33

    Article  CAS  PubMed  Google Scholar 

  8. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W (2011) Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 11(4):274–286

    Article  PubMed Central  PubMed  Google Scholar 

  9. http://www.ensembl.org/Homo_sapiens/Location/View?db=core;r=7:99365033-99365133;v=rs4646437;vdb=variation;vf=3543993.

  10. Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH (2012) The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics 22(5):373–380

    CAS  PubMed  Google Scholar 

  11. Schirmer M, Rosenberger A, Klein K, Kulle B, Toliat MR, Nurnberg P et al (2007) Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics 8(5):443–453

    Article  CAS  PubMed  Google Scholar 

  12. Sheng X, Zhang L, Tong N, Luo D, Wang M, Xu M et al (2012) MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case-control studies. Mol Biol Rep 39(7):7237–7249

    Article  CAS  PubMed  Google Scholar 

  13. Dulucq S, Krajinovic M (2010) The pharmacogenetics of imanitib. Genome Med 2(11):85

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Cho JH, Yoon YD, Park JY, Song EJ, Choi JY, Yoon SH et al (2012) Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. Transplant Proc 44(1):109–114

    Article  CAS  PubMed  Google Scholar 

  15. Hammann F, Hruz P, Kullak-Ublick G, Vavricka SR, Beglinger C, Drewe J et al (2012) Determination of the single nucleotide polymorphisms C3435 and G2677T in MDR1 and C421A in BCRP in blood samples of patients with inflammatory bowel disease and healthy controls in the Swiss population. Metabolomics 2:104

    Google Scholar 

  16. Kubista M, Andrade JM, Bengtsson M, Forootan A, Jonak J, Lind K et al (2006) The real-time polymerase chain reaction. Mol Aspects Med 27(2–3):95–12517

    Article  CAS  PubMed  Google Scholar 

  17. Schirmer M, Rosenberger A, Klein K, Kulle B, Toliat MR, Nurnberg P et al (2007) Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics 8(5):443–453

    Article  CAS  PubMed  Google Scholar 

  18. Oneda B, Crettol S, Jaquenoud Sirot E, Bochud M, Ansermot N, Eap CB (2009) The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics 19(11):877–883

    Article  CAS  PubMed  Google Scholar 

  19. Cho JH, Yoon YD, Park JY, Song EJ, Choi JY, Yoon SH et al (2012) Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. Transplant Proc 44(1):109–114

    Article  CAS  PubMed  Google Scholar 

  20. Fanta S, Niemi M, Jonsson S, Karlsson MO, Holmberg C, Neuvonen PJ et al (2008) Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics 18(2):77–90

    Article  CAS  PubMed  Google Scholar 

  21. Singh R, Kesarwani P, Srivastava A, Mittal RD (2008) ABCB1 G2677 allele is associated with high dose requirement of cyclosporin A to prevent renal allograft rejection in North India. Arch Med Res 39(7):695–701

    Article  CAS  PubMed  Google Scholar 

  22. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y (2007) CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 82(6):711–725

    Article  CAS  PubMed  Google Scholar 

  23. Satoh S, Saito M, Inoue T, Kagaya H, Miura M, Inoue K et al (2009) CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients. Eur J Clin Pharmacol 65(5):473–481

    Article  CAS  PubMed  Google Scholar 

  24. Song P, Li S, Meibohm B, Gaber AO, Honaker MR, Kotb M et al (2002) Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. AAPS Pharm Sci 4(4):E29

    Article  Google Scholar 

  25. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC et al (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14(3):147–154

    Article  CAS  PubMed  Google Scholar 

  26. Fredericks S, Jorga A, MacPhee IA, Reboux S, Shiferaw E, Moreton M et al (2007) Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on cyclosporin dose requirements as assessed by C0 or C2 measurements. Clin Transplant 21(2):252–257

    Article  PubMed  Google Scholar 

  27. Foote CJ, Greer W, Kiberd B, Fraser A, Lawen J, Nashan B et al (2007) Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. Transplantation 83(10):1380–1384

    Article  CAS  PubMed  Google Scholar 

  28. Choi JH, Lee YJ, Jang SB, Lee JE, Kim KH, Park K (2007) Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol 64(2):185–191

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt

    Ola Sharaki, Pacint Moez, Nermine Hossam Zakaria & Eman Nassar

  2. Internal Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt

    Montasser Zeid

Authors
  1. Ola Sharaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Montasser Zeid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pacint Moez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nermine Hossam Zakaria
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eman Nassar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nermine Hossam Zakaria.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharaki, O., Zeid, M., Moez, P. et al. Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients. Mol Biol Rep 42, 105–117 (2015). https://doi.org/10.1007/s11033-014-3747-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-014-3747-8

Keywords

Search

Navigation